Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

BACKGROUND: In rituximab-treated patients with rheumatoid arthritis, humoral and cellular immune responses after two or three doses of SARS-CoV-2 vaccines are not well characterised. We aimed to address this knowledge gap. METHODS: This prospective, cohort study (Nor-vaC) was done at two hospitals i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jyssum, Ingrid, Kared, Hassen, Tran, Trung T, Tveter, Anne T, Provan, Sella A, Sexton, Joseph, Jørgensen, Kristin K, Jahnsen, Jørgen, Kro, Grete B, Warren, David J, Vaage, Eline B, Kvien, Tore K, Nissen-Meyer, Lise-Sofie H, Anderson, Ane Marie, Grødeland, Gunnveig, Haavardsholm, Espen A, Vaage, John Torgils, Mjaaland, Siri, Syversen, Silje Watterdal, Lund-Johansen, Fridtjof, Munthe, Ludvig A, Goll, Guro Løvik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700278/
https://www.ncbi.nlm.nih.gov/pubmed/34977602
http://dx.doi.org/10.1016/S2665-9913(21)00394-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700278/
https://www.ncbi.nlm.nih.gov/pubmed/34977602
http://dx.doi.org/10.1016/S2665-9913(21)00394-5

Ejemplares similares